• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

婴儿血管瘤的危险因素:荟萃分析。

Risk factors for infantile hemangioma: a meta-analysis.

机构信息

Department of Dermatology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830000, China.

出版信息

World J Pediatr. 2020 Aug;16(4):377-384. doi: 10.1007/s12519-019-00327-2. Epub 2019 Dec 18.

DOI:10.1007/s12519-019-00327-2
PMID:31853885
Abstract

BACKGROUND

Infantile hemangioma (IH) is one of the most common tumors in infants. Its pathogenesis is complex and poorly understood. The risk factors of IH have been extensively studied from clinical and epidemiological perspectives in recent years, but the conclusions in the literature reports are inconsistent. To provide a reference for the prevention of hemangioma, we conducted a meta-analysis of the published studies of potential risk factors for IH.

METHODS

The Cochrane Library, Ovid, PubMed, and Web of Science databases were searched systematically. Log odds ratios (log ORs), logistic regression standard errors and 95% confidence intervals (CIs) were used to compare the correlation between IH and potential risk factors. Review Manager 5.3.3 was used for the statistical analysis.

RESULTS

Six studies were included and 17 potential risk factors were eventually evaluated. P values < 0.05 were found for female gender (P < 0.01, OR 2.04, 95% CI 1.65-2.51), low birth weight (P < 0.01, OR 4.39, 95% CI 3.05-6.31), multiple gestation (P = 0.01, OR 2.39, 95% CI 1.21-4.71), preterm birth (P = 0.03, OR 2.37, 95% CI 1.07-5.23), progesterone therapy (P < 0.01, OR 2.73, 95% CI 2.12-3.51), and family history (P = 0.01, OR 1.98, 95% CI 1.16-3.38).

CONCLUSIONS

This meta-analysis revealed that risk factors, including female gender, low birth weight, multiple gestation, preterm birth, progesterone therapy, and family history may affect the occurrence of IH.

摘要

背景

婴儿血管瘤(IH)是婴儿中最常见的肿瘤之一。其发病机制复杂,尚未完全阐明。近年来,从临床和流行病学角度广泛研究了 IH 的危险因素,但文献报道的结论不一致。为了为血管瘤的预防提供参考,我们对已发表的 IH 潜在危险因素的研究进行了荟萃分析。

方法

系统检索 Cochrane 图书馆、Ovid、PubMed 和 Web of Science 数据库。使用对数优势比(log OR)、逻辑回归标准误差和 95%置信区间(CI)比较 IH 与潜在危险因素之间的相关性。使用 Review Manager 5.3.3 进行统计分析。

结果

纳入 6 项研究,最终评估了 17 个潜在危险因素。女性性别(P<0.01,OR 2.04,95%CI 1.65-2.51)、低出生体重(P<0.01,OR 4.39,95%CI 3.05-6.31)、多胎妊娠(P=0.01,OR 2.39,95%CI 1.21-4.71)、早产(P=0.03,OR 2.37,95%CI 1.07-5.23)、孕激素治疗(P<0.01,OR 2.73,95%CI 2.12-3.51)和家族史(P=0.01,OR 1.98,95%CI 1.16-3.38)的 P 值均<0.05。

结论

本荟萃分析显示,危险因素包括女性性别、低出生体重、多胎妊娠、早产、孕激素治疗和家族史可能会影响 IH 的发生。

相似文献

1
Risk factors for infantile hemangioma: a meta-analysis.婴儿血管瘤的危险因素:荟萃分析。
World J Pediatr. 2020 Aug;16(4):377-384. doi: 10.1007/s12519-019-00327-2. Epub 2019 Dec 18.
2
Tocolysis with the β-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants.使用β-拟交感神经药非诺特罗进行保胎治疗不会增加早产和足月产婴儿患婴幼儿血管瘤的几率。
Arch Gynecol Obstet. 2018 Sep;298(3):521-527. doi: 10.1007/s00404-018-4830-5. Epub 2018 Jun 25.
3
Clinical and epidemiological risk factors for infantile hemangioma: A case-control study.婴幼儿血管瘤的临床和流行病学危险因素:病例对照研究。
Pediatr Dermatol. 2023 Jul-Aug;40(4):647-650. doi: 10.1111/pde.15363. Epub 2023 Jun 14.
4
The prevalence, complications, and risk factors for infantile hemangioma: a systematic review and meta-analysis.婴幼儿血管瘤的患病率、并发症及危险因素:系统评价和荟萃分析。
Int J Dermatol. 2024 Jun;63(6):737-746. doi: 10.1111/ijd.17062. Epub 2024 Feb 8.
5
Maternal and perinatal risk factors for infantile hemangioma: a case-control study.婴儿血管瘤的母婴及围产期危险因素:一项病例对照研究。
Pediatr Dermatol. 2013 Jul-Aug;30(4):457-61. doi: 10.1111/pde.12042. Epub 2012 Dec 26.
6
Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants.婴儿血管瘤:一个与低体重儿出生率上升相关的新出现的健康问题。
J Pediatr. 2008 Nov;153(5):712-5, 715.e1. doi: 10.1016/j.jpeds.2008.05.043.
7
Analysis of onset and clinical characteristics in Japanese patients with infantile hemangioma.分析日本婴儿血管瘤患者的发病和临床特征。
Drug Discov Ther. 2021 Sep 22;15(4):210-213. doi: 10.5582/ddt.2021.01066. Epub 2021 Aug 26.
8
Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment.婴幼儿血管瘤:风险因素、发病机制和治疗的最新综述。
Birth Defects Res. 2017 Jul 3;109(11):809-815. doi: 10.1002/bdr2.1023. Epub 2017 Apr 12.
9
Temporal trends in prenatal risk factors for the development of infantile hemangiomas.婴儿血管瘤发生的产前危险因素的时间趋势。
Pediatr Dermatol. 2018 Nov;35(6):787-791. doi: 10.1111/pde.13659. Epub 2018 Sep 6.
10
A retrospective study to classify surgical indications for infantile hemangiomas.一项回顾性研究,旨在对婴儿血管瘤的手术适应证进行分类。
J Plast Reconstr Aesthet Surg. 2014 Sep;67(9):1215-21. doi: 10.1016/j.bjps.2014.05.007. Epub 2014 May 16.

引用本文的文献

1
Infantile Hemangioma: Risk Factors and Management in a Preterm Patient-A Case Report.婴儿血管瘤:一名早产儿患者的危险因素及管理——病例报告
Reports (MDPI). 2024 Jan 1;7(1):3. doi: 10.3390/reports7010003.
2
Clinical Insights into Risk Factors for Infantile Hemangioma and Propranolol Treatment Outcomes.婴儿血管瘤危险因素及普萘洛尔治疗效果的临床见解
Diagnostics (Basel). 2025 Jul 16;15(14):1792. doi: 10.3390/diagnostics15141792.
3
Imaging of infantile hemangiomas: a pictorial essay.婴儿血管瘤的影像学表现:图文综述
Radiol Bras. 2025 Jul 10;58:e20250041. doi: 10.1590/0100-3984.2025.0041-en. eCollection 2025 Jan-Dec.
4
Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors.缺氧驱动的血管肿瘤血管生成与代谢重编程
Front Cell Dev Biol. 2025 May 15;13:1572909. doi: 10.3389/fcell.2025.1572909. eCollection 2025.
5
Impact of congenital heart disease on clinical outcomes of oral propranolol therapy for Infantile hemangiomas: a propensity score-matched analysis.先天性心脏病对婴儿血管瘤口服普萘洛尔治疗临床结局的影响:一项倾向评分匹配分析
BMC Pediatr. 2025 May 3;25(1):354. doi: 10.1186/s12887-025-05707-4.
6
Analysis of infantile hemangioma without proliferation after birth.出生后无增殖的婴儿血管瘤分析。
GHM Open. 2024 Nov 30;4(2):80-83. doi: 10.35772/ghmo.2023.01022.
7
Oral propranolol and its impact on vital signs in hospitalized pediatric patients for the Management of Infantile Hemangiomas.口服普萘洛尔及其对住院小儿患者生命体征的影响,用于婴儿血管瘤的治疗
Pediatr Dermatol. 2025 Mar-Apr;42(2):245-250. doi: 10.1111/pde.15740. Epub 2025 Feb 18.
8
Nanotechnology in Infantile Hemangioma Management.纳米技术在婴幼儿血管瘤治疗中的应用
J Pediatr Pharmacol Ther. 2025 Feb;30(1):27-46. doi: 10.5863/1551-6776-30.1.27. Epub 2025 Feb 10.
9
The Evaluation, Diagnosis, and Management of Infantile Hemangiomas-A Comprehensive Review.婴儿血管瘤的评估、诊断与管理——全面综述
J Clin Med. 2025 Jan 10;14(2):425. doi: 10.3390/jcm14020425.
10
Optimizing Propranolol Therapy for Infantile Hemangiomas: The Role of the Multidisciplinary Team.优化普萘洛尔治疗婴幼儿血管瘤:多学科团队的作用。
Cureus. 2024 Dec 16;16(12):e75806. doi: 10.7759/cureus.75806. eCollection 2024 Dec.